CompletedPhase 3

Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles

United Kingdom210 participantsStarted 2003-07

Plain-language summary

RATIONALE: Drugs used in chemotherapy, such as bleomycin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of bleomycin is more effective when given together with etoposide and cisplatin in treating metastatic germ cell cancer of the testicles. PURPOSE: This randomized phase III trial is studying two different schedules of bleomycin to compare how well they work when given together with etoposide and cisplatin in treating patients with metastatic germ cell cancer of the testicles.

Who can participate

Age range18 Years – 50 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of metastatic germ cell cancer of the testes * Good-prognosis disease * Eligible for treatment with bleomycin, etoposide, and cisplatin PATIENT CHARACTERISTICS: * Creatinine clearance ≥ 60 mL/min * No other prior or concurrent malignancy except basal cell skin cancer * No other major systemic illness * No impaired respiratory function, including any of the following: * Shortness of breath on minimal exertion * Hypoxia at rest * Carbon monoxide transfer, total lung capacity, and FEV\_1 \> 60% of predicted PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy

What they're measuring

Pulmonary toxicity

Trial details

NCT IDNCT00324298

SponsorQueen Mary University of London

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Drug/Agent Toxicity by Tissue/Organ trials